国际药学研究杂志
國際藥學研究雜誌
국제약학연구잡지
INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH
2014年
3期
342-347
,共6页
刘越%王立宽%孙德佳%王勃%李锦
劉越%王立寬%孫德佳%王勃%李錦
류월%왕립관%손덕가%왕발%리금
替米沙坦%小胶质细胞%脂多糖%过氧化物酶体增殖物激活受体γ
替米沙坦%小膠質細胞%脂多糖%過氧化物酶體增殖物激活受體γ
체미사탄%소효질세포%지다당%과양화물매체증식물격활수체γ
telmisartan%microglia%lipopolysaccharide%peroxisome proliferator-activated receptor-γ
目的:研究替米沙坦改善脂多糖(lipopolysaccharide,LPS)诱导的小胶质细胞炎症反应是否与其激活过氧化物酶体增殖物激活受体γ(peroxisome proliferator-activated receptor γ,PPARγ)进而促进小胶质细胞激活表型转化有关。方法采用荧光素酶报告基因检测方法研究替米沙坦对PPARγ的激动活性;建立LPS诱导的小鼠BV-2小胶质细胞炎症模型,在该模型上用0.1~10 mol/L替米沙坦单独处理BV-2细胞,或者1μmol/L替米沙坦与10μmol/L PPARγ特异性阻断剂GW9662共同处理BV-2细胞,用ELISA法检测细胞上清中肿瘤坏死因子-α(tumor necrosis factor-alpha,TNF-α)的含量,用实时定量PCR法检测BV-2小胶质细胞M1型细胞标志物(CD16、CD11b、iNOS)和M2型细胞标记物IL-10的mRNA表达水平变化。结果与溶剂对照组相比,0.1~10 mol/L替米沙坦能浓度依赖地激活PPARγ,对荧光素酶的诱导倍数分别为1.29、1.36和1.45(均P<0.01);在LPS诱导的BV-2小胶质细胞炎症模型上,与溶剂对照组相比,LPS处理组细胞上清中TNF-α的含量显著升高(P<0.01),小胶质细胞M1型标记物CD16、CD11b和iNOS mRNA表达水平显著上调(P<0.05);与LPS处理组相比,0.1~10 mol/L替米沙坦能浓度依赖地降低小胶质细胞上清中TNF-α的含量(P<0.05),10 mol/L替米沙坦能显著下调小胶质细胞M1型标记物CD16、CD11b和iNOS 的mRNA表达水平(P<0.01和P<0.05),且0.1 mol/L替米沙坦能显著上调小胶质细胞M2型标记物IL-10的mRNA表达水平(P<0.05);与1 mol/L替米沙坦处理组相比,PPARγ特异性阻断剂GW9662能显著上调CD16的mRNA表达水平(P<0.05)。结论替米沙坦显著抑制LPS诱导的小胶质细胞激活后TNF-α的释放,其作用机制可能与替米沙坦激活PPARγ并促进小胶质细胞M1/M2激活表型的转化密切相关。
目的:研究替米沙坦改善脂多糖(lipopolysaccharide,LPS)誘導的小膠質細胞炎癥反應是否與其激活過氧化物酶體增殖物激活受體γ(peroxisome proliferator-activated receptor γ,PPARγ)進而促進小膠質細胞激活錶型轉化有關。方法採用熒光素酶報告基因檢測方法研究替米沙坦對PPARγ的激動活性;建立LPS誘導的小鼠BV-2小膠質細胞炎癥模型,在該模型上用0.1~10 mol/L替米沙坦單獨處理BV-2細胞,或者1μmol/L替米沙坦與10μmol/L PPARγ特異性阻斷劑GW9662共同處理BV-2細胞,用ELISA法檢測細胞上清中腫瘤壞死因子-α(tumor necrosis factor-alpha,TNF-α)的含量,用實時定量PCR法檢測BV-2小膠質細胞M1型細胞標誌物(CD16、CD11b、iNOS)和M2型細胞標記物IL-10的mRNA錶達水平變化。結果與溶劑對照組相比,0.1~10 mol/L替米沙坦能濃度依賴地激活PPARγ,對熒光素酶的誘導倍數分彆為1.29、1.36和1.45(均P<0.01);在LPS誘導的BV-2小膠質細胞炎癥模型上,與溶劑對照組相比,LPS處理組細胞上清中TNF-α的含量顯著升高(P<0.01),小膠質細胞M1型標記物CD16、CD11b和iNOS mRNA錶達水平顯著上調(P<0.05);與LPS處理組相比,0.1~10 mol/L替米沙坦能濃度依賴地降低小膠質細胞上清中TNF-α的含量(P<0.05),10 mol/L替米沙坦能顯著下調小膠質細胞M1型標記物CD16、CD11b和iNOS 的mRNA錶達水平(P<0.01和P<0.05),且0.1 mol/L替米沙坦能顯著上調小膠質細胞M2型標記物IL-10的mRNA錶達水平(P<0.05);與1 mol/L替米沙坦處理組相比,PPARγ特異性阻斷劑GW9662能顯著上調CD16的mRNA錶達水平(P<0.05)。結論替米沙坦顯著抑製LPS誘導的小膠質細胞激活後TNF-α的釋放,其作用機製可能與替米沙坦激活PPARγ併促進小膠質細胞M1/M2激活錶型的轉化密切相關。
목적:연구체미사탄개선지다당(lipopolysaccharide,LPS)유도적소효질세포염증반응시부여기격활과양화물매체증식물격활수체γ(peroxisome proliferator-activated receptor γ,PPARγ)진이촉진소효질세포격활표형전화유관。방법채용형광소매보고기인검측방법연구체미사탄대PPARγ적격동활성;건립LPS유도적소서BV-2소효질세포염증모형,재해모형상용0.1~10 mol/L체미사탄단독처리BV-2세포,혹자1μmol/L체미사탄여10μmol/L PPARγ특이성조단제GW9662공동처리BV-2세포,용ELISA법검측세포상청중종류배사인자-α(tumor necrosis factor-alpha,TNF-α)적함량,용실시정량PCR법검측BV-2소효질세포M1형세포표지물(CD16、CD11b、iNOS)화M2형세포표기물IL-10적mRNA표체수평변화。결과여용제대조조상비,0.1~10 mol/L체미사탄능농도의뢰지격활PPARγ,대형광소매적유도배수분별위1.29、1.36화1.45(균P<0.01);재LPS유도적BV-2소효질세포염증모형상,여용제대조조상비,LPS처리조세포상청중TNF-α적함량현저승고(P<0.01),소효질세포M1형표기물CD16、CD11b화iNOS mRNA표체수평현저상조(P<0.05);여LPS처리조상비,0.1~10 mol/L체미사탄능농도의뢰지강저소효질세포상청중TNF-α적함량(P<0.05),10 mol/L체미사탄능현저하조소효질세포M1형표기물CD16、CD11b화iNOS 적mRNA표체수평(P<0.01화P<0.05),차0.1 mol/L체미사탄능현저상조소효질세포M2형표기물IL-10적mRNA표체수평(P<0.05);여1 mol/L체미사탄처리조상비,PPARγ특이성조단제GW9662능현저상조CD16적mRNA표체수평(P<0.05)。결론체미사탄현저억제LPS유도적소효질세포격활후TNF-α적석방,기작용궤제가능여체미사탄격활PPARγ병촉진소효질세포M1/M2격활표형적전화밀절상관。
Objective To evaluate the ameliorative effect of telmisartan on the inflammatory reaction induced by lipopolysaccharide(LPS) in microglia cells and investigate its effect on modulation of activated microglia phenotype transformation by activation of the peroxisome proliferator-activated receptor γ (PPARγ) accordingly. Methods The PPARγ agonistic activity of telmisartan was explored using PPARγ-responsive element- lucifarase reporter assay ,and inflammatory model was established through LPS-induced microglia cells. The mice microglia cells (BV-2 microglia cell line) were treated in the presence of telmisartan ranging from 0.1 to 10 μmol/L or in the presence of 1 mol/L telmisartan with 10 μmol/L GW9662, the specific PPARγ antagonist. The contents of tumor necrosis factor-alpha (TNF-α ) in cell supernatants were analyzed by ELISA; the mRNA expression level of M1 phenotype markers CD16, CD11b and iNOS as well as M2 phenotype marker IL-10 were evaluated using the real-time quantitative PCR. Results Compared with control group, telmisartan could concentration-dependently activate the PPARγ ranging from 0.1 to 10 μmol/L and the relative lucifarase activity induced by telmisartan was 1.29, 1.36 and 1.45 folds (P<0.01), respectively; in the inflammatory model of BV-2 cells induced by LPS, compared with control group, the content of TNF-α in cell supernatants significantly increased (P<0.01) and the mRNA expression level of M1 phenotype microglia markers CD16, CD11b and iNOS was significantly up-regulated (P<0.05) in LPS group; compared with LPS group, telmisartan could concentration-dependently decreased the content of TNF-α in cell supernatants arranging from 0.1 to 10 mol/L (P<0.05); 10 mol/L telmisartan could significantly down-regulated the mRNA expression level of M1 phenotype microglia markers CD16, CD11b and iNOS (P<0.01, P<0.05 and P<0.05) ; additionally, 0.1 μmol/L telmisartan could significantly up-regulated the mRNA expression level of M2 phenotype microglia marker IL-10 (P<0.05); compared with 1 mol/L telmisartan treated group, the mRNA expression level of CD16 was significantly up-regulated by specific PPARγ antagonist GW9662 (P<0.05). Conclusion Telmisartan could markedly reduce the release of TNF-α in LPS-induced activated microglia cells; the mechanism is associated with modulating the transformation of M1/M2 microglia phenotype by the activation of PPARγ.